FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 582 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Reunión anual de la American Society of Clinical Oncology de 2023:... June 2, 2023 New plan unveiled to tackle Scotland’s cancer crisis June 16, 2023 什么是癌症的肿瘤标志物检测？您需要需要知道的 8 件事 June 24, 2021 5 Tips for Managing Financial Stress During Cancer April 19, 2022 Load more HOT NEWS Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive,... Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active... FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy New on NCI’s Websites for June 2023
